| · | | |
|--|---|---|
| | Application No. | Applicant(s) |
| Matica of Allamahilita | 08/965,356 | BERNFIELD ET AL. |
| Notice of Allowability | Examiner | Art Unit |
| | Anne-Marie Falk, Ph.D. | 1632 |
| The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308. | | |
| 1. This communication is responsive to the BPAI decision of 11/22/04. | | |
| 2. The allowed claim(s) is/are <u>6 and 15</u> . | | |
| 3. The drawings filed on 6/14/99 are accepted by the Examiner. | | |
| 4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: | | |
| Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. | | |
| 5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. | | |
| 6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. | | |
| (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached | | |
| 1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date | | |
| (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date | | |
| identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). | | |
| 7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. | | |
| Attachment(s) | | |
| 1. Notice of References Cited (PTO-892) | 5. Notice of Informal Pa | atent Application (PTO-152) |
| 2. Notice of Draftperson's Patent Drawing Review (PTO-948) | 6. Interview Summary | |
| Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date | Paper No./Mail Date 8), 7. ⊠ Examiner's Amendm | Paper No./Mail Date 7. ⊠ Examiner's Amendment/Comment |
| Examiner's Comment Regarding Requirement for Deposit of Biological Material | 8. ☐ Examiner's Stateme 9. ☐ Other | nt of Reasons for Allowance |
| | Ą | Inne-Marie Falk |
| | | ANNE-MARIE FALK, PH.D |

Examiner's Amendment

Claims 1, 3-6, 10, and 12-15 remain pending in the instant application, after the Board of Patent Appeals and Interferences decision dated November 22, 2004.

During a telephone conversation conducted on March 24, 2005, Patrea Pabst authorized the following examiner's amendment. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

In the Claims:

Claims 1, 3-5, 10, and 12-14 are cancelled.

6. A transgenic rodent whose genome comprises a stably integrated DNA sequence encoding a syndecan operably linked to a promoter, wherein expression of the DNA sequence results in the rodent developing maturity onset obesity, the rodent having the genotype FVB/N-TgN(synd-1).

Conclusion

Upon entry of the foregoing amendment, Claims 6 and 15 are allowable.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne-Marie Falk whose telephone number is (571) 272-0728. The examiner can normally be reached Monday through Friday from 10:30 AM to 7:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, can be reached on (571) 272-0735. The central official fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Anne-Marie Falk, Ph.D.

Anne-Marie Falk, PH.D
PRIMARY EXAMINER